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Abstract
Osteopontin is a multifunctional protein with known roles in bone remodeling, wound healing, and normal and pathological immune responses. We showed in microarray studies that osteopontin gene expression is increased in human immunodeficiency virus type 1 (HIV-1)–infected lymphatic tissues after treatment, and we undertook mapping
experiments to study osteopontin’s possible functions in this context. We discovered species-specific colocalization of
osteopontin with the follicular dendritic cell (FDC) network in lymphatic tissues in HIV-1 and simian immunodeficiency virus infections, and we found that changes in FDC-associated osteopontin covary with changes in lymphoid
follicles during acute and late stages of infection and in response to treatment. We propose that this localization normally facilitates antibody production and plays a role in B cell abnormalities in infection and in the reconstitution of
lymphoid follicles with treatment and that mapping genes identified in microarray studies is a useful experimental
approach to gaining a better understanding of function in the context of a particular tissue and disease.

O

steopontin is a secreted, phosphorylated, acidic
glycoprotein that was first identified in studies of
bone repair but was subsequently shown to have multiple functions in the repair of other tissues, immune responses, and inflammation [1, 2]. In mineralized tissues,
osteopontin binds to the extracellular matrix through interactions between its asparagine-glycine-aspartate sequence and integrins, and it regulates calcium deposition during the stress-induced remodeling of bone.
In other tissues, osteopontin promotes wound healing and inhibits ectopic calcification [3–5]. Osteopontin also functions in the induction of cellular and humoral immune responses [6–8] and participates in both
physiological inflammation during wound healing and
immune responses and pathological inflammatory conditions that include arthritides [9, 10], multiple sclerosis
1269

[11], and autoimmune diseases [8, 12, 13].
We recently found that osteopontin gene expression increased in HIV-1–infected lymphatic tissues after the institution of highly active antiretroviral therapy (HAART) [14]. We provisionally interpreted this
result as possible evidence of the wound-healing functions of osteopontin (described above) in a previously
unexamined tissue, but we sought further insight into
osteopontin’s functions in the reparative response to
HAART in lymphatic tissues by mapping the localization of osteopontin. During the course of these studies,
we discovered a previously unrecognized association
of osteopontin with the follicular dendritic-cell (FDC)
network of humans and primates but not that of mice,
and we propose that this species-specific association reflects the evolution of osteopontin to facilitate antibody
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production. In support of this hypothesis, we document
(1) changes in FDC-associated osteopontin that parallel
the well-known hypergammaglobulinemia and B cell
abnormalities observed during the early stages of HIV-1
and simian immunodeficiency virus (SIV) infections, (2)
decreases in FDC-associated osteopontin that parallel
the destruction of lymphoid follicles during late stages
of infection, and (3) during HAART, a coordinate normalization of follicular architecture and FDC-associated
osteopontin.
Material and Methods
Human lymph-node biopsies. After we obtained signed,
informed consent, inguinal lymph-node biopsies were
performed, by use of standard surgical techniques, on
individuals under local anesthesia who were participating in University of Minnesota institutional review
board–approved protocols [15]. A portion of the tissue
was placed in 4% paraformaldehyde for 3–4 h and was
then transferred to 70% ethanol and embedded in paraffin for in situ hybridization, immunohistochemical
staining, and histological examination.
Lymph-node biopsies from SIV-infected rhesus macaques. Axillary lymph-node biopsies were performed
on adult female SIV- and simian retrovirus–negative
rhesus macaques under anesthesia before and 1 and 4
weeks after intravenous (iv) inoculation with 2 × 104
ID50 of SIVmac239 (provided by R. Desrosiers, New
England National Primate Research Center, Southborough, MA). All animal housing, care, and research were
performed in accordance with the Guide for the Care and
Use of Laboratory Animals [16] and with protocols approved by the Institutional Animal Care and Use Committee of the National Cancer Institute.
Immunohistochemical staining. For immunohistochemical staining, after blocking to reduce nonspecific
binding, sections were reacted sequentially with primary antibody, biotinylated secondary antibody, and
ABC reagent, and then were stained with diaminobenzidine and counterstained with hematoxylineosin. For
osteopontin staining, we used monoclonal antibodies to human osteopontin peptides at the C terminus 3
aa from the thrombin cleavage site (Immuno-Biological
Laboratories), goat polyclonal antibodies to full-length
recombinant mouse osteopontin (AF808; R&D Systems)
and proteolytically derived Nand C-terminal fragments
(provided by L. Fisher, National Institute of Dental and
Craniofacial Research, National Institutes of Health,
Bethesda, MD) [17, 18], rabbit polyclonal antibodies to
full-length and N- and C-terminal fragments of recombinant mouse osteopontin (provided by L. Liaw, Maine
Medical Center Research Institute, Scarborough, ME),
and rabbit polyclonal antibodies that recognize fulllength and C-terminal fragments of osteopontin and
cross-react with human, pig, and dog osteopontin (abcam 8448; Novus Biologicals).
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In situ hybridization. Tissue sections of 8 µm were
cut and adhered to slides, deparaffinized, and subsequently pretreated for the detection of HIV RNA by
in situ hybridization, as described elsewhere [19]. In
brief, sections were pretreated with HCl, digitonin, and
proteinase K, to enhance the diffusion of probes, and
then acetylated, to reduce the nonspecific binding of
probes. After the hybridization of a collection of 35S-labeled HIV-1–specific riboprobes, sections were washed,
treated with ribonuclease, dehydrated, coated with
NTB2 (Kodak), and developed and stained after radioautographic exposure. For osteopontin, cDNA from
the American Type Culture Collection (ATCC number
61052) was subcloned into the pBluescript II SK(-) plasmid, and an 35S-labeled riboprobe was prepared by incorporation of the label with T7 RNA polymerase.
Statistical analysis. A random-effects model was
used to determine the statistical significance of changes
in the percentage of FDC-associated osteopontin/lymphatic tissue area attributable to HAART. This analysis
was necessary for combining information from 2 small,
slightly different studies. The model assumed that the
changes in each individual were normally distributed,
given some study-specific mean effect, and that these
study-specific mean effects were drawn from another
normal distribution. The mean of the latter distribution
was the estimate of the effect due to HAART. A Bayesian approach was used, and computation was done by
first integrating the variance parameters out of the posterior distribution, then directly sampling the other 3
parameters from a histogram approximation of their
posterior distribution. Calculations were conducted by
use of S-plus software (version 3.4; MathSoft).
Results
FDC-associated osteopontin in HIV-1–infected and –uninfected lymphatic tissues as revealed by mapping studies. With the rationale that knowing where osteopontin
was expressed in lymphatic tissues would provide additional clues to its function, we determined sites of osteopontin expression by immunohistochemical staining.
We had expected from the results of other studies [1, 20]
that we would detect osteopontin in cells, but we had
not seen a report of an association of osteopontin with
lymphoid follicles. We were thus surprised to find that
(1) before treatment, during the late stage of HIV-1 infection, osteopontin colocalized with the FDC network
in small residual secondary follicles; and (2) 2 months
after the initiation of HAART, there was increased osteopontin staining in a pattern characteristic of the FDC
network in the large follicles that had reformed by that
time (Figure 1A and 1B). We confirmed the colocalization of osteopontin protein with the FDC network by
staining for the FDC marker CD35 and by revealing,
through in situ hybridization, the virions bound to the
FDC network [19] before treatment (Figure 1C and 1D).
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Figure 1. Follicular dendritic cell (FDC)–associated osteopontin.
A and B, Detection of
FDC-associated osteopontin by immunohistochemical staining
with a monoclonal antibody to a human osteopontin peptide at
the C terminus in an
HIV-1–infected individual in the late
stages of infection before (A) and after (B)
2 months of highly active antiretroviral therapy (HAART). Note
the follicular pattern of
staining and increased
size of the follicle and
osteopontin staining
after HAART.
C and D, Double-label in situ hybridization to detect HIV-1
RNA in virions bound
to the FDC network
and immunohistochemical staining for
osteopontin.
C, Bright silver grains
after in situ hybridization with 35S-labeled HIV-1–specific
riboprobes to detect
FDC-associated virions colocalizing
with brown-staining
osteopontin.
D, Double-label for
CD35 to mark the
FDC network (red
stain) colocalizing
with gray-staining osteopontin showing
colocalization.
E, Osteopontin staining
at high magnification
(×40) of the FDC network in an HIV-1–uninfected individual.

1272

Q. Li

et al. in

Journal

of

Infectious Diseases 192 (2005)

Figure 2. A, Detection of osteopontin
mRNA in cells in the paracortical T cell
zone but not follicles. Brightly illuminated
silver grains overlying cells but not
follicles are evident in the section after
in situ hybridization with HIV-1–specific
35S-labeled riboprobes. B and C, Detection
of osteopontin in T cells and macrophages.
Arrows indicate doubly labeled T cells and
macrophages, stained with anti-CD3 or
anti-CD68, respectively, and osteopontin
stained with the monoclonal antibody to
the human osteopontin peptide described
in the Figure 1 legend.

We then investigated and documented osteopontin colocali zation with the FDC network in follicles in other
HIV-1–infected and –uninfected individuals (Figure 1E).
Binding but not production of osteopontin by FDCs.
Although the FDC network clearly binds osteopontin, we did not detect osteopontin mRNA in FDCs by
in situ hybridization, although we did detect osteopontin mRNA (Figure 2A) in cells in the paracortical T
cell zone identified by double-label staining as T cells
and macrophages (Figure 2B and 2C).We conclude that
these cells are the local source of osteopontin that binds
to the FDC network.
Increase in FDC-associated osteopontin during
HAART. We found that the size of the follicles and FDCassociated osteopontin gene expression (Figure 1A and
1B) increased in parallel, which suggests that follicle formation and osteopontin synthesis and binding are concurrently regulated. Because the FDC network is slowly
reconstituted during HAART [21], we would therefore expect corresponding increases in FDC-associated osteopontin gene expression. We quantified FDCassociated osteopontin as a percentage of the area of

lymphatic tissues stained by antibody in a total of 12
individuals in 2 separate studies over the course of 1.5
years of HAART; indeed, we found, in a meta-analysis
of the separate studies, statistically significant increases
(P = .02) in FDC-associated osteopontin gene expression that closely matched the increases previously documented in the FDC network (data not shown) [21].
Increase in FDC-associated osteopontin gene expression during acute SIV infection. The increases in both
osteopontin gene expression and the number and size
of lymphoid follicles imply that FDC-bound osteopontin gene expression should also increase with the welldocumented and particularly dramatic increases in the
numbers and sizes of the follicles during the early stage
of HIV-1 infection [22]. For obvious practical and ethical reasons, lymph-node biopsies cannot be obtained
during the relevant time frame (before and shortly after HIV-1 infection) for testing this hypothesis. However, we were able to study lymph nodes obtained before and during acute SIV infection of rhesus macaques,
a nonhuman primate model in which the changes in
lymphatic tissues correspond closely to those in HIV-1
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Figure 3. Osteopontin in
follicles and cells of a simian immunodeficiency virus (SIV)–infected rhesus
macaque.
A, Follicular dendritic cell–
associated osteopontin
and 2 cells (arrow, inset).
B, Increased osteopontin in
follicles in early SIV infection. Increased osteopontin staining, using
the monoclonal antibody
to the human osteopontin peptide described in
the Figure 1 legend, paralleled the increased nos.
and sizes of follicles in biopsies from 3 macaques
from baseline to 1 and 4
weeks after intravenous
infection.
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Figure 4. Osteopontin-positive cells but no follicular dendritic cell (FDC)–associated osteopontin in sections from a B6 mouse
lymph node. Osteopontin was detected with rabbit polyclonal antibody to a 32-KDa C-terminal fragment of recombinant mouse
osteopontin. Arrows indicate osteopontin-positive cells in the encircled follicle with no detectable staining of the FDC network.

infection [23, 24]. Osteopontin colocalized to the rhesus macaque FDC network (Figure 3A) and to cells in
the paracortex (Figure 3A, inset); in accordance with the
hypothesis, FDCbound osteopontin gene expression increased substantially and proportionately with the increased numbers and sizes of the follicles accompanying immune activation in response to infection at 1 and
4 weeks after IV infection with SIV (Figure 3).
No detection of FDC-associated osteopontin gene
expression in the mouse. In addition to the follicular hyperplasia described above, polyclonal B cell activation
and hypergammaglobulinemia are also characteristic
of early HIV-1 infection [24–27]. Because the increased
FDC-associated osteopontin gene expression observed
in acute SIV infection pointed to a potential role of osteopontin in these B cell abnormalities that we could
not directly test in fixed tissues, we designed experiments with model antigens to examine the relationship
between osteopontin gene expression and antibody
production in mice. Because we had not seen descriptions of osteopontin colocalizing with the FDC network

in mice, and because of the many examples of differences in mouse and human immune systems [28], we
first undertook some preliminary experiments to determine whether osteopontin was, in fact, associated with
murine FDCs. Although the osteopontin antibodies
readily detected osteopontin-positive cells in the paracortex and follicles (Figure 4) of mouse (B6 and other
strains) lymph nodes, there was no detectable FDC-associated osteopontin in polyclonal and monoclonal antibodies to full-length recombinant mouse osteopontin
and proteolytically derived N- and C-terminal fragments. Thus, osteopontin’s association with the FDC
network is species specific.
Discussion
In the present studies, we found that (1) there is a speciesspecific association of osteopontin with the FDC network
and (2) changes in the levels of FDC-associated osteopontin gene expression are correlated with pathological abnormalities in lymphoid follicles in HIV-1 and SIV
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infections and the reparative response to HAART. We
now discuss what these findings might imply about FDCassociated osteopontin’s roles, both normally in antibody
production and in immunodeficiency virus infections.
The association of osteopontin with the FDC network
locates a powerful antibody-stimulating cytokine in the
lymphoid follicle structure, which is organized to bring
together antigen bound to the FDC network, B cells, and
germinal-center CD4+ cells to stimulate B cell proliferation and differentiation for the production of high-affinity antibodies. The FDC-associated osteopontin could be
contributing to antibody production at this site by facilitating FDC–CD4+ cell germinal-center interactions that
augment Th1 cytokine and CD40L expression. Because
osteopontin is known to augment CD40L expression in
T cells [32], FDC-associated osteopontin is ideally sited
anatomically to increase the expression of CD40L on
CD4+ cells in close proximity to B cells, thereby inducing B cell proliferation and antibody production.
Osteopontin in mice, similarly, has long been known
to stimulate antibody production and B cell proliferation through CD40-CD40L and other interactions with
CD4+ cells. T cells and macrophages also produce osteopontin in mice, just as we have shown in humans and
nonhuman primates. However, osteopontin was not detectably bound by FDCs in mice, in contrast to what was
seen in primate species. Although the murine and human osteopontin sequences are closely related [33–35],
we conclude from the present studies that the additional
sequences that osteopontin has acquired through evolution enable it to bind to FDCs for the facilitation of antibody production.
In all 3 species, elevated levels of osteopontin were
implicated in B cell abnormalities. In mice, high levels of
osteopontin were associated with polyclonal B cell activation, autoimmune disease, and murine AIDS, respectively, in MRL/lpr mice, osteopontintransgenic mice,
and mice infected with the retrovirus LP-BM5 [8, 12, 13,
20]. In human and nonhuman primate lymphatic tissues, changes in the levels of FDC-associated osteopontin that could be contributing to the B cell abnormalities
observed in HIV-1 and SIV infections and to the pathological changes in lymphoid follicles in these infections
that cover a spectrum from follicular hyperplasia, to involution, to the development of lymphomas [22, 29].
During the early stages of infection, the deposition of viral immune complexes in the FDC network is associated
with increases in the number and size of the follicles
and with the concomitant generalized polyclonal activation of B cells that results in hypergammaglobulinemia
[24, 26, 27, 30]. Recent evidence has suggested that hyperactivated naive B cells are responsible for increased
immunoglobulin production [31] and that the abnormal
differentiation of naive B cells is driven by CD40-CD40L
interactions that would be enhanced by FDCassociated
osteopontin gene expression.
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By the later stages of infection, HIV-1 and SIV have
destroyed lymphoid follicles, with accompanying defects in the humoral immune response to recall antigens
and vaccination that reflect structural damage and reductions in the number of memory B cells [31]. We had
shown previously that this destructive process is reversible by HAART. During HAART, follicles reformed over
a period from a few months to 1.5 years of treatment; by
the latter time point, levels were similar in proportion
to numbers of follicles in HIV-1–uninfected individuals
[36]. Here, we have provided encouraging evidence that
the capacity to regenerate FDC-associated osteopontin is
retained as another component of the immune reconstitution that takes place during HAART.
Finally, the present studies illustrate how mapping
the cellular and anatomic location of genes discovered in microarray studies can help define function in
a particular tissue and disease. In particular, in the immunodeficiency virus infection of lymphatic tissues,
there would have been no a priori reason or literature
on osteopontin to suspect binding to FDCs and, therefore, a potentially new role in normal and abnormal B
cell states. Thus, mapping studies can complement gene
profiling by pointing the way forward from hypothesis
generation to hypothesis testing.
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